Montelukast (as sodium)

Description

Empowering Respiratory Wellness with PharmAlliance International Labs’ Montelukast Tablets

Welcome to PharmAlliance International Labs Private Limited, where innovation meets excellence in pharmaceutical care. Introducing our Montelukast Tablets, meticulously crafted to provide effective relief for patients battling asthma and allergic rhinitis. At PharmAlliance, we are dedicated to delivering high-quality pharmaceutical products that empower healthcare professionals and patients alike to overcome respiratory challenges and embrace a life of wellness.

Understanding the Drug Class:

Montelukast belongs to the esteemed class of leukotriene receptor antagonists, renowned for their targeted approach to respiratory inflammation. By selectively inhibiting the action of leukotriene D4 at the cysteinyl leukotriene receptor, Montelukast mitigates bronchoconstriction and inflammation associated with asthma and allergic rhinitis. This mechanism of action makes it a cornerstone in the management of respiratory conditions, offering patients a pathway to better respiratory health and improved symptom control.

Tailored Formulations for Optimal Convenience:

Our Montelukast Tablets are available in 5mg and 10mg strengths, offering flexibility and precision in dosage administration. Packaged in blister packs containing 14 tablets each, our oral tablets are designed for convenient use, ensuring accurate dosing and ease of storage. Whether prescribed for asthma prophylaxis or the relief of allergic rhinitis symptoms, PharmAlliance’s Montelukast Tablets provide patients with a reliable solution for respiratory management.

Comprehensive Indications and Usage Guidelines:

PharmAlliance’s Montelukast Tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients aged 12 months and older. Additionally, they offer relief from symptoms of allergic rhinitis, including nasal congestion, sneezing, itching, and rhinorrhea. With clear dosage instructions and flexible administration options, our Montelukast Tablets empower patients to take control of their respiratory health and embrace a life free from the constraints of respiratory discomfort.

Pharmacokinetics and Pharmacodynamics:

Montelukast is well absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within 3 to 4 hours following oral administration. Metabolized extensively in the liver via cytochrome P450 enzymes, Montelukast and its metabolites are primarily excreted in the feces. Pharmacologically, Montelukast exerts its effects by selectively antagonizing the leukotriene D4 receptor, thereby reducing bronchoconstriction, airway inflammation, mucous secretion, and edema associated with asthma and allergic rhinitis.

Safety and Side Effects Monitoring:

While generally well-tolerated, Montelukast Tablets may cause some common side effects such as headache, abdominal pain, diarrhea, nausea, and fatigue. Rare but serious side effects, including neuropsychiatric events, should be monitored closely, and healthcare providers should be informed of any concerning symptoms. At PharmAlliance, patient safety is paramount, and we remain committed to providing healthcare professionals with the necessary resources to ensure optimal patient care and safety.

Experience Relief with PharmAlliance International Labs:

Trust PharmAlliance International Labs Private Limited as your partner in respiratory wellness. With our Montelukast Tablets, patients can experience effective relief from asthma and allergic rhinitis symptoms, enabling them to lead healthier, more fulfilling lives. For more information about our innovative pharmaceutical solutions, please contact us. Together, let’s embark on a journey towards respiratory wellness and empower patients to breathe easier with confidence.